AU Patent

AU2025203941A1 — Methods Of Treating Small Cell Lung Cancer With Lurbinectedin Formulations

Assigned to Pharmamar SA · Expires 2025-06-19 · 1y expired

What this patent protects

#$%^&*AU2025203941A120250619.pdf##### ABSTRACT Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination …

USPTO Abstract

#$%^&*AU2025203941A120250619.pdf##### ABSTRACT Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided. 95 90 so 50 100 150 200 Temperature (C) Fig. 3

Drugs covered by this patent

Patent Metadata

Patent number
AU2025203941A1
Jurisdiction
AU
Classification
—
Expires
2025-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Pharmamar SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.